2020 Fiscal Year Final Research Report
Prediction of prolonged jaundice for preterm infant persistent using blood carbon monoxide concentration and UGT1A1 gene mutation
Project/Area Number |
19K17344
|
Research Category |
Grant-in-Aid for Early-Career Scientists
|
Allocation Type | Multi-year Fund |
Review Section |
Basic Section 52050:Embryonic medicine and pediatrics-related
|
Research Institution | Nihon University |
Principal Investigator |
KATO Ryota 日本大学, 医学部, 助手 (60838481)
|
Project Period (FY) |
2019-04-01 – 2021-03-31
|
Keywords | 黄疸 / 早産児 / UGT1A1遺伝子 / 一酸化炭素 |
Outline of Final Research Achievements |
The purpose of this study is to develop a quantitative measurement method for carbon monoxide (CO) in the blood of preterm infants, and to examine whether blood CO concentration and/or Uridine diphosphate glucuronosyltransferase1A1 (UGT1A1) gene mutation would develop jaundice after 2 weeks of age. We developed a quantitative measurement method for CO in the blood of preterm infants. However, for its clinical application, it was considered necessary to devise ways to control the volatility of CO. We also identified breastfeeding and UGT1A1 gene mutations (*6) as clinical predictive factors of preterm infants with jaundice after 2 weeks of age.
|
Free Research Field |
新生児医学
|
Academic Significance and Societal Importance of the Research Achievements |
新生児黄疸の原因であるビリルビンは、神経毒性を有し、アテトーゼ型脳性麻痺や難聴を引き起こす(ビリルビン脳症)。生後2週間以降に黄疸が増強する早産児を未然に予測できれば、ビリルビン脳症の発症抑制に大きく寄与できるが、その予測方法がなかった。今回、その臨床予測因子として、母乳栄養およびUGT1A1遺伝子変異が明らかになった。出生直後にUGT1A1遺伝子変異の確認を行うというテーラーメード診断を行い、早期治療を行うことで、早産児のビリルビン脳症の発症を予防できる。
|